Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System

Background. Cladribine belongs to the group of disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS). According to the highlights of a meeting held by the Pharmacovigilance Risk Assessment Committee (PRAC) on 14 January 2022, cladribine may be associated with the occurrence of liv...

Descripción completa

Detalles Bibliográficos
Autores principales: Velișcu, Elena Mirabela, Liguori, Valerio, Anatriello, Antonietta, Maniscalco, Giorgia Teresa, Cantone, Andrea, Di Costanzo, Luigi, Stefanelli, Pasquale, Scavone, Cristina, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459297/
https://www.ncbi.nlm.nih.gov/pubmed/37630986
http://dx.doi.org/10.3390/ph16081071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459297/
https://www.ncbi.nlm.nih.gov/pubmed/37630986
http://dx.doi.org/10.3390/ph16081071

Ejemplares similares